Off-Label Use of Type 2 Diabetes Medications in Type 1 Diabetes: Benefits, Risks, and Clinical Guidance

Insulin therapy remains the cornerstone of treatment for people with type 1 diabetes, but a growing number of clinicians are exploring the off-label use of medications approved for type 2 diabetes to help improve outcomes beyond what insulin alone can achieve.

When a medication is prescribed for a purpose not approved by the U.S. Food and Drug Administration, it is considered off-label use. In the context of type 1 diabetes, drugs such as metformin, GLP-1 receptor agonists like semaglutide (Ozempic) and tirzepatide (Mounjaro), and SGLT-2 inhibitors are being used to help patients reach A1C goals, reduce insulin requirements, and manage weight.

While these adjunct therapies offer potential benefits, they also come with increased risks, including hypoglycemia and diabetic ketoacidosis (DKA). Medical experts emphasize that none of these medications should be used without close clinical supervision.

Metformin: A Long-Standing Option with Modest Benefits

Metformin, a first-line treatment for type 2 diabetes for decades, is sometimes prescribed off-label for people with type 1 diabetes. It works by decreasing hepatic glucose production and improving insulin sensitivity.

For individuals with type 1 diabetes, metformin may help reduce total daily insulin needs. One systematic review and meta-analysis found that in adolescents, metformin lowered insulin requirements by an average of 0.61 units per kilogram, while in adults, the reduction was 0.44 units per kilogram. The medication may also modestly reduce A1C by approximately 0.3 percentage points and support weight loss or body mass index reduction in both age groups, although these effects may be temporary.

Some evidence suggests metformin could improve insulin resistance and offer cardiovascular benefits, though data remains mixed. However, its use carries risks, including gastrointestinal side effects such as nausea and diarrhea, and a small risk of hypoglycemia. Rarely, metformin-associated lactic acidosis can occur, particularly in individuals with impaired kidney function, necessitating careful evaluation before initiation.

GLP-1 Receptor Agonists: Weight and Blood Sugar Management

GLP-1 receptor agonists, including semaglutide (Ozempic) and tirzepatide (Mounjaro), are increasingly prescribed off-label for people with type 1 diabetes, especially those with obesity or high insulin demands. These drugs mimic the action of the glucagon-like peptide-1 hormone, enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety.

Clinicians report that GLP-1 therapy can lead to meaningful weight loss, modest improvements in blood sugar control, and reduced daily insulin requirements. By improving insulin sensitivity, these medications may lessen the amount of exogenous insulin needed. GLP-1s have demonstrated broader metabolic benefits, including potential reductions in blood pressure and cholesterol, and improvements in kidney health, which may help mitigate long-term complications of type 1 diabetes.

Despite these advantages, GLP-1 use in type 1 diabetes is associated with gastrointestinal side effects such as nausea, vomiting, and diarrhea. There is also a risk of hypoglycemia, particularly when insulin sensitivity increases rapidly and insulin doses are not adjusted accordingly. While uncommon, GLP-1 agonists may contribute to the risk of diabetic ketoacidosis, potentially due to dehydration from vomiting or diarrhea. To mitigate risks, clinicians often initiate treatment with low doses and maintain close monitoring in collaboration with endocrinologists.

SGLT-2 Inhibitors: Promising Outcomes with Notable Risks

SGLT-2 inhibitors work by blocking the sodium-glucose cotransporter-2 in the kidneys, preventing glucose reabsorption and promoting its excretion in urine. This mechanism effectively lowers blood sugar levels and has been described by clinicians as “making you pee out sugar.”

In people with type 1 diabetes, SGLT-2 inhibitor use has been associated with improvements in A1C ranging from 0.20 to 0.45 percentage points, increased time in range, and weight loss. One study reported an average 4.4% reduction in body weight after one year of treatment, with some trials in overweight individuals showing up to a 13.3% reduction in body weight with empagliflozin. These medications may also significantly reduce basal insulin needs and lower the risk of heart failure and chronic kidney disease, although long-term data in type 1 diabetes remain limited.

The most significant concern with SGLT-2 inhibitors in type 1 diabetes is the increased risk of diabetic ketoacidosis. Unlike typical DKA, which presents with markedly elevated blood sugar, euglycemic DKA can occur even when glucose levels are only moderately high or within the normal range. This risk is heightened in individuals following low-carbohydrate diets. Because SGLT-2 inhibitors increase urinary glucose excretion, they may also raise susceptibility to genital and urinary tract infections. As with other glucose-lowering agents, hypoglycemia remains a possible side effect.

Clinical Guidance and the Path Forward

Medical professionals stress that any consideration of off-label medication use in type 1 diabetes must involve thorough discussion with a healthcare provider. Patients are advised to consult their endocrinologist to understand the potential benefits and risks, proceed cautiously with dosing, and utilize tools such as continuous glucose monitoring to detect early signs of hypoglycemia or metabolic imbalance.

As interest in adjunctive therapies grows, ongoing research aims to better define the role of metformin, GLP-1 receptor agonists, and SGLT-2 inhibitors in type 1 diabetes management. Until more definitive data emerge, the consensus remains clear: these medications may offer meaningful support but must be used judiciously and under expert supervision to ensure safety.